title: Technology evaluation: APC-80200, Dendreon.
abstract: APC-80200 (Mylovenge) has been developed for the treatment of B-cell malignancies and is currently in phase II clinical trials as a therapeutic vaccine for patients with advanced multiple myeloma. This vaccine candidate appears to be of particular benefit in patients who have received high-dose chemotherapy to reduce tumor load following stem cell rescue. APC-80200 is also being tested in patients with amyloidosis.
authors.affiliation: Mater Medical Research Institute, South Brisbane, Queensland, Australia.
authors.forename: Alison
authors.initials: A
authors.lastname: Rice
authors.forename: Derek
authors.initials: D
authors.lastname: Hart
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D013673:Technology Assessment, Biomedical
chemical_list: D019496:Cancer Vaccines